CRISPR and Beta-Thalassemia (BT)

This up-to-date roundup presents the 7 clinical-stage gene-editing approaches to sickle cell disease, which affects millions of people worldwide and...

This week's clinical update features news from Editas Medicine, which recently announced that the U.S. Food and Drug Administration (FDA) has granted...

This week, we provide a roundup of the ongoing gene-editing trials for beta thalassemia. This update includes trials sponsored by Vertex...

In this piece, we provide selected highlights from the 63rd American Society of Hematology annual meeting, held from December 11-14th 2021.

On Monday, Beam Therapeutics announced that the U.S. FDA had cleared BEAM-101 for clinical evaluation as a treatment for sickle cell disease. BEAM-101...

This week’s clinical update looks at a Phase 1 trial for ET-01, a CRISPR-edited blood cell therapy for beta thalassemia.

CRISPR-based blood cell therapies are advancing through clinical trials, with promising results stacking up for certain rare genetic diseases and some...

β-Thalassemia is caused in part by a mutated β-globin gene, so researchers developed a way to replace the entire mutated gene with a healthy version...